Abstract:1550 Background: Immune checkpoint blockades (ICBs) have drastically improved the clinical outcomes of cancer patients, while only ~30% of them get significant benefits from immunotherapy. TMB, PD-L1, TNB, GEP (Cristescu et al. 2018) and other conventional biomarkers can explain only ~60% of the ICB response, suggesting that novel factors are yet to be discovered. Methods: Gene expression profiles and clinical information of 672 patients were collected from IMvigor210 (n=348, bladder cancer), Pender et al. (n=98, 20 tumor types), Kim et al. (n=45, gastric cancer) and CheckMate (n=181, kidney cancer) cohorts, in which all patients were treated with ICBs. In each sample, gene expression intensities normalized by RPKM were ranked in descender order (range of 1-20000) and scaled into the 0-1 range lastly. To identify immune signatures that correlated with both response and survival, 1000+ immune genes were downloaded from InnatDB database, and their expression values were compared between the two groups of IMvigor210 data which were divided according to response (CR+PR vs. SD+PD, Wilcoxon test) or overall survival (≥mOS vs. <mOS, Cox survival analysis). Bayesian-regularization neural networks (BRNN) model was used to develop the risk model to predict ICB response and prognosis. 75% of IMvigor210 data were randomly selected as the training set, and the remaining 25% as the test set. The performance of predictor was independently validated in Pender et al., Kim et al., and CheckMate cohorts subsequently. ROC curves were used to evaluate the predictive accuracy to response. Survival plots were created using the Kaplan-Meier estimator, and data were analyzed by log-rank test. Results: 40 DEGs (including top20 DEGs positively correlated with ORR/OS and top20 DEGs negatively correlated with ORR/OS) were identified as immune signatures, in which each gene signature could significantly distinguish ICB response and survival. Our model outperformed TMB or GEP in the prediction of response in IMvigor210 (Model = 0.986 vs. TMB = 0.728 vs. GEP = 0.551), Pender et al. (Model = 0.757 vs. TMB = 0.593 vs. GEP = 0.621), Kim et al. (Model = 0.881 vs. GEP = 0.828), and CheckMate (Model = 0.927 vs. TMB = 0.543) cohorts when AUC was used as performance metric. Meanwhile, our model showed promising results for differentiating longer survivors from shorter survivors with p vale <0.0001, 0.064, 0.021, and 0.0006 in IMvigor210, Pender et al., Kim et al., and CheckMate cohorts respectively. Conclusions: We proposed a deep learning model to predict ICB response and survival, in which feature selection based on immune gene expression order, allowing all kinds of platforms and expression data types. Our model showed a robust prediction not only in bladder cancer, but also in other pan-cancer types.

Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer

Immune Landscape of Invasive Ductal Carcinoma Tumour Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature

Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response

Preoperative immunological plasma markers TRAIL, CSF1 and TIE2 predict survival after resection for biliary tract cancer

Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma

Establish TIIC signature score based the machine learning fusion in bladder cancer

Liquid Biopsy-Based Prediction of Clinical Benefit from Immune Checkpoint Inhibitors in Advanced Biliary Tract Cancer.

Gene expression-based machine learning approach to predict immunotherapy response and survival in patients with advanced cancer.

Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer

Integration of Bioinformatics and Machine Learning to Identify CD8+ T Cell-Related Prognostic Signature to Predict Clinical Outcomes and Treatment Response in Breast Cancer Patients

A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors

Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes

Comprehensively analysis of immunophenotyping signature in triple-negative breast cancer patients based on machine learning

Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer

Single-cell Atlas of Diverse Immune Populations in the Advanced Biliary Tract Cancer Microenvironment

Integrated machine learning algorithms reveal a bone metastasis-related signature of circulating tumor cells in prostate cancer

Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes